Search results for "Density"

showing 10 items of 4402 documents

The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates

2007

Beyond total low-density-lipoproteins (LDL) levels, increasing evidence suggests that the 'quality' of LDL exerts a great influence on the cardiovascular risk. Several studies have also shown that the therapeutic modulation of LDL size is of benefit in reducing the risk of cardiovascular events. Hypolipidaemic treatment is able to alter LDL subclass distribution but strong variations have been noticed among different agents. Fibrates have a major impact on triglyceride metabolism and in modulating LDL size and subclasses, but variations exist among the different molecules.A literature search (by Medline and Scopus) was performed using the following headings: 'small dense LDL', 'LDL size', '…

medicine.medical_specialtySmall dense ldlClofibric AcidFenofibrateInternal medicinemedicineLow densityHumansGemfibrozilClinical significanceParticle SizeDyslipidemiasHypolipidemic AgentsBezafibrateFenofibratebusiness.industryBezafibrateDense low density lipoproteinFenofibrate Gemfibrozil Subfractions TherapyLdl subfractionsFibric AcidsGeneral MedicineLipoproteins LDLTreatment OutcomeEndocrinologylipids (amino acids peptides and proteins)CiprofibrateBezafibrateGemfibrozilbusinessmedicine.drug
researchProduct

Analysis of radiolucent gallstones by computed tomography for in vivo estimation of stone components.

1990

. Successful oral litholytic and other non-operative therapies of gallstones require exact determination of the stone components. Since computed tomography (CT) provides highly sensitive measurement of density, we performed a study to evaluate whether CT measurement of stone density allows a prediction of the composition of radiolucent gallstones. Twenty-eight patients presenting with 29 radiolucent gallbladder (n= 17) or common bile duct stones (n=12) were included. Prior to operative or endo-scopic therapy the attenuation values (Hounsfield Units, HU) were assessed in vivo by CT under standardized conditions (Somatom II, 125 KV, 130 mAs). After surgical or endoscopic stone removal the con…

medicine.medical_specialtySpectrophotometry Infraredmedicine.medical_treatmentRadiodensityClinical BiochemistryPalmitic AcidPalmitic AcidsBiochemistrySensitivity and SpecificityCalcium CarbonateIn vivoCholelithiasisHounsfield scalemedicineHumansCommon bile ductbusiness.industryGallbladderProteinsBilirubinGeneral MedicineGallstonesmedicine.diseaseExtracorporeal shock wave lithotripsyUrsodeoxycholic acidmedicine.anatomical_structureCholesterolRadiologybusinessTomography X-Ray Computedmedicine.drugEuropean journal of clinical investigation
researchProduct

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart diseas…

2013

AIMS: The first aim was to critically evaluate the extent to which familial hypercholesterolaemia (FH) is underdiagnosed and undertreated. The second aim was to provide guidance for screening and treatment of FH, in order to prevent coronary heart disease (CHD).METHODS AND RESULTS: Of the theoretical estimated prevalence of 1/500 for heterozygous FH, <1% are diagnosed in most countries. Recently, direct screening in a Northern European general population diagnosed approximately 1/200 with heterozygous FH. All reported studies document failure to achieve recommended LDL cholesterol targets in a large proportion of individuals with FH, and up to 13-fold increased risk of CHD. Based on prev…

medicine.medical_specialtyStatinAtherosclerosis; Cardiovascular disease; Cholesterol; Coronary heart disease; Low-density lipoproteinSettore MED/09 - Medicina Internamedicine.drug_classPopulationCHILDRENFamilial hypercholesterolemiaBile acid bindingCOST-EFFECTIVENESS ANALYSIS030204 cardiovascular system & hematologyLDL-CHOLESTEROLDIAGNOSIS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeInternal medicineDiabetes mellitusmedicineMANAGEMENT030212 general & internal medicineeducationHealth aging / healthy living Cardiovascular diseases [IGMD 5]Alirocumabeducation.field_of_studyCYTOKINE PATTERN CHANGEbusiness.industryLow-density lipoproteinmedicine.diseaseAtherosclerosisCardiovascular diseaseLomitapideDENSITY-LIPOPROTEIN APHERESIS3. Good healthASSOCIATION EXPERT PANELCoronary heart diseaseEndocrinologyCholesterolchemistryCARDIOVASCULAR-DISEASEAtherosclerosiCardiology and Cardiovascular MedicinebusinessSTATIN TREATMENTmedicine.drugEuropean Heart Journal
researchProduct

Plain film, CT and MRI sensibility in the evaluation of intraorbital foreign bodies in an in vitro model of the orbit and in pig eyes.

2000

Detection and characterization of intraorbital foreign bodies (IFB) is fundamental in acute trauma setting, preventing inflammatory sequelae or complications related to IFB movements when a MRI study is planned. Papers concerning plain film and CT sensibility in IFB detection show controversial results. For this reason we investigated plain film, CT and MRI sensibility in the evaluation of IFB. For an in vitro model, specimens of dry and fresh wood, glass, iron, plastic and graphite were immersed in animal lard and in a 0.9 % sodium chloride plus 3.5 g/dl human serum albumin solution. Specimens of different size and nature where also implanted into enucleated pig eyes. Air bubbles were intr…

medicine.medical_specialtySwineRadiodensityRadiographyPlain filmEyeSensitivity and SpecificityIn vitro modelmedicineAnimalsHumansRadiology Nuclear Medicine and imagingmedicine.diagnostic_testbusiness.industryUltrasoundMagnetic resonance imagingGeneral MedicineMagnetic Resonance ImagingEye Injuries Penetratingmedicine.anatomical_structureEye Foreign BodiesTomographyRadiologybusinessTomography X-Ray ComputedOrbitOrbit (anatomy)European radiology
researchProduct

Oxidative Modification of Low-Density Lipoprotein and Atherogenetic Risk in β-Thalassemia

1998

AbstractWe investigated the oxidative state of low-density lipoprotein (LDL) in patients with β-thalassemia to determine whether there was an association with atherogenesis. Conjugated diene lipid hydroperoxides (CD) and the level of major lipid antioxidants in LDL, as well as modified LDL protein, were evaluated in 35 β-thalassemia intermedia patients, aged 10 to 60, and compared with age-matched healthy controls. Vitamin E and β-carotene levels in LDL from patients were 45% and 24% of that observed in healthy controls, respectively. In contrast, the mean amount of LDL-CD was threefold higher and lysil residues of apo B-100 were decreased by 17%. LDL-CD in thalassemia patients showed a str…

medicine.medical_specialtyThalassemiamedicine.medical_treatmentImmunologymedicine.disease_causeBiochemistryLipid peroxidationchemistry.chemical_compoundInternal medicinemedicinebiologybusiness.industryVitamin ECell BiologyHematologyMalondialdehydemedicine.diseaseFerritinEndocrinologychemistryLow-density lipoproteinbiology.proteinlipids (amino acids peptides and proteins)businessOxidative stressLipoproteinBlood
researchProduct

Influence of long-term postmenopausal hormone-replacement therapy on estimated structural bone strength: A study in discordant monozygotic twins

2010

Although postmenopausal hormone-replacement therapy (HRT) is known to prevent fractures, knowledge on the influence of long-term HRT on bone strength and its determinants other than areal bone mineral density is scarce. This study used a genetically controlled design with 24 monozygotic female twin pairs aged 54 to 72 years in which one cotwin was using HRT (mean duration 8 years) and the other had never used HRT. Estimated bone strength, cross-sectional area, volumetric bone mineral density, bone mineral mass, and cross-sectional density and mass distributions were assessed in the tibial shaft, distal tibia, and distal radius with peripheral computed tomography (pQCT). In the tibial shaft,…

medicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentDentistryMonozygotic twin030209 endocrinology & metabolismBone and Bones03 medical and health sciences0302 clinical medicineBone strengthBone DensitymedicineHumansPostmenopausal Hormone Replacement TherapyOrthopedics and Sports Medicineta315Aged030304 developmental biologyBone mineral0303 health sciencesPostmenopausal womenAnthropometrybusiness.industryEstrogen Replacement Therapyta3141Hormone replacement therapy (menopause)Organ SizeTwins Monozygoticta3142Middle AgedHormonesConfidence intervalSurgerymedicine.anatomical_structureBody CompositionFemaleCortical boneDiaphysesSelf ReportbusinessJournal of Bone and Mineral Research
researchProduct

Effect of CYP1A1 Gene Polymorphisms on Estrogen Metabolism and Bone Density

2004

UNLABELLED: In this study, we evaluated the effect of polymorphisms of the CYP1A1 gene, linked to hormone-related cancers, on estrogen metabolism and BMD. We found that variants carrying the A allele (CA and AA) for the C4887A polymorphism have a significantly higher degree of estrogen catabolism and lower femoral BMD. INTRODUCTION: Polymorphisms of the CYP1A1 gene, one of the key enzymes that metabolize estrogen, have been linked with hormone-related cancers. We investigated the impact of these polymorphisms on estrogen metabolism and BMD, which is another hormone-dependent health issue. MATERIALS AND METHODS: One hundred seventy postmenopausal women (mean age, 63.5 +/- 0.6 years) particip…

medicine.medical_specialtyTime FactorsGenotypeBone densitymedicine.drug_classEndocrinology Diabetes and MetabolismOsteoporosisRadioimmunoassayBiologyArticleCollagen Type IBone resorptionImmunoenzyme TechniquesAbsorptiometry PhotonBone DensityRisk FactorsInternal medicinehormones and receptorGenotypeCytochrome P-450 CYP1A1medicineHumansosteoporosiOrthopedics and Sports MedicineFemurBone ResorptionAllelesAgedPolymorphism GeneticEstradiolgenetic researchEstrogensMiddle Agedmedicine.diseaseGenotype frequencyPostmenopauseMenopauseEndocrinologyEstrogenepidemiologyFemaleCollagenGene polymorphismMenopausePeptidesPolymorphism Restriction Fragment LengthJournal of Bone and Mineral Research
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence-a multi-centre study

2011

Abstract Introduction Bisphosphonates (BPs) are powerful drugs that inhibit bone metabolism. Adverse side effects are rare but potentially severe such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, research has primarily focused on the development and progression of BRONJ in cancer patients with bone metastasis, who have received high dosages of BPs intravenously. However, a potential dilemma may arise from a far larger cohort, namely the millions of osteoporosis patients on long-term oral BP therapy. Patients and methods This current study assessed 470 cases of BRONJ diagnosed between 2004 and 2008 at eleven different European clinical centres and has resulted in the …

medicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.medical_treatmentOral Surgical ProceduresOsteoporosisAdministration OralSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansMedical historyAdverse effectBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryContraindicationsOsteonecrosisBisphosphonatemedicine.diseaseSurgeryZoledronic acidOtorhinolaryngologyCohortOral and maxillofacial surgeryOsteoporosisSurgeryOral Surgeryosteoporosis bisphosphonates ostenecrosis jawsOsteonecrosis of the jawbusinessJaw Diseasesmedicine.drug
researchProduct

Determination of renal tissue ibandronate levels in rats with normal and mildly impaired renal function

2013

After entering the blood, bisphosphonates are immediately bound to bone or excreted unchanged by the kidney. During renal excretion about 0.5% of administrated dosage remains in kidney tissue. The renal tissue level of bisphosphonates (RTL) decreases over time and remains at about 0.15% after 3weeks, but the influence of renal insufficiency (RI) is unclear.We investigated the influence of mild to moderate RI on RTL of ibandronate (IBD). First a method for determination of RTL was implemented and validated. We measured RTL in rats with normal renal function (SHAM) and after unilateral nephrectomy (UNX). In each case one SHAM and one UNX groups received one or alternatively 9 times every 3wee…

medicine.medical_specialtyTime FactorsUrologyKidneyToxicologySeverity of Illness IndexImpaired renal functionNormal renal functionmedicineAnimalsTissue DistributionRenal InsufficiencyRats WistarIbandronic AcidPharmacologyKidneyBone Density Conservation AgentsDiphosphonatesbusiness.industryRenal tissueUnilateral nephrectomyRatsSurgeryDisease Models Animalmedicine.anatomical_structureRenal physiologyFemalebusinessHalf-LifeJournal of Pharmacological and Toxicological Methods
researchProduct